We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings

30 hedge funds and large institutions have $28.5M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less capital invested

Capital invested by funds: $34.6M → $28.5M (-$6.11M)

19% less funds holding

Funds holding: 37 → 30 (-7)

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
30
Holders Change
-7
Holders Change %
-18.92%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
7
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$587K
2
Millennium Management
Millennium Management
New York
+$96.5K
3
E
Ergoteles
New York
+$48.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$33.8K
5
IAIM
International Assets Investment Management
Florida
+$23.1K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$927K
2
CCM
CAAS Capital Management
New York
-$252K
3
BBA
Baker Bros. Advisors
New York
-$243K
4
BlackRock
BlackRock
New York
-$189K
5
UBS Group
UBS Group
Switzerland
-$67K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$6.5M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$4.8M -$927K -577,682 -17%
BBA
3
Baker Bros. Advisors
New York
$4.11M -$243K -151,522 -6%
OMC
4
OUP Management Company
Pennsylvania
$4.06M -$16K -10,000 -0.4%
APM
5
Avidity Partners Management
Texas
$2.96M -$16.7K -10,400 -0.6%
NM
6
Newtyn Management
New York
$1.68M +$587K +365,888 +56%
Vanguard Group
7
Vanguard Group
Pennsylvania
$965K +$467 +291 +0%
CCM
8
CAAS Capital Management
New York
$759K -$252K -157,043 -25%
LCM
9
Laurion Capital Management
New York
$593K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$378K -$60.4K -37,628 -14%
Millennium Management
11
Millennium Management
New York
$296K +$96.5K +60,132 +50%
RC
12
RBF Capital
California
$250K -$1.76K -1,100 -0.7%
EWM
13
Evercore Wealth Management
New York
$242K – – –
BCM
14
Bridgeway Capital Management
Texas
$197K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$193K +$5.62K +3,504 +3%
BlackRock
16
BlackRock
New York
$131K -$189K -117,568 -60%
Morgan Stanley
17
Morgan Stanley
New York
$49.9K -$62.7K -39,062 -56%
E
18
Ergoteles
New York
$49.7K +$48.4K +30,148 New
Two Sigma Advisers
19
Two Sigma Advisers
New York
$42.9K -$3.69K -2,300 -8%
Bank of America
20
Bank of America
North Carolina
$40.9K +$6.11K +3,810 +18%
State Street
21
State Street
Massachusetts
$39.4K – – –
Citadel Advisors
22
Citadel Advisors
Florida
$34.7K +$33.8K +21,044 New
CC
23
Cannell Capital
Wyoming
$32.5K – – –
Northern Trust
24
Northern Trust
Illinois
$24.6K +$2.78K +1,732 +13%
IAIM
25
International Assets Investment Management
Florida
$23.8K +$23.1K +14,400 New
1
2

CYT Hedge Fund Activity: Q4 2022 in Review

30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q4 2022, worth a combined $28.5M — down 18% from $34.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CYT and 4 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was Newtyn Management, adding an estimated $587K. The largest seller was Fidelity Investments, cutting an estimated $927K.

  • 30 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q4 2022, down from 37 in Q3 2022.
  • Funds reported $28.5M of Cyteir Therapeutics, Inc. Common Stock stock for Q4 2022, down 18% quarter-over-quarter.
  • 4 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -6 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q4 2022 was Newtyn Management, an estimated $587K added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $927K sold.

Based on aggregated 13F filings for Q4 2022.